You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 6,004,968

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,004,968

Title:	Pharmaceutical compositions containing lamivudine
Abstract:	The present invention relates to pharmaceutical formulations containing (2R, cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2 -one (-)-2',3'-dideoxy,3'-thiacytidine, lamivudine, that are substantially free of ethanol and ethylenediamine-tetraacitic acid, and their use in medical therapy.
Inventor(s):	Casey; Warren Michael (Knightdale, NC), Nguyen; Ngoc-Anh Thi (Durham, NC)
Assignee:	Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:	09/044,896
Patent Claims:	1. A pharmaceutical composition, substantially free of ethanol and ethylenediaminetetraacetic acid, comprising lamivudine or a pharmaceutically acceptable derivative thereof, and a preservative system. 2. A pharmaceutical composition comprising lamivudine, said composition being substantially free of ethanol and ethylenediaminetetraacetic acid and exhibiting antimicrobial preservative efficacy. 3. A pharmaceutical composition as claimed in claim 2, further comprising parabens, said composition having a pH greater than 5.5. 4. A pharmaceutical composition, substantially free of ethanol and ethylenediaminetetraacetic acid, comprising lamivudine or a pharmaceutically acceptable derivative thereof, methyl paraben, and propyl paraben, said composition having a pH greater than 5.5. 5. A pharmaceutical composition according to claim 4 wherein the concentration of methyl paraben is 0.96 mg/mL to 2 mg/mL and the concentration of propyl paraben is 0.1 mg/mL to 0.2 mg/mL. 6. A pharmaceutical composition according to claim 4 wherein the pH is in the range 5.56-7.4. 7. A pharmaceutical composition according to claim 6 wherein the pH is 6.0. 8. A pharmaceutical composition as claimed in claim 4 wherein the amount of lamivudine is in the range of 0.1-100 mg/mL. 9. A pharmaceutical composition as claimed in claim 8 wherein the amount of lamivudine is in the range of 5-20 mg/mL. 10. A pharmaceutical composition as claimed in claim 4 further comprising a second therapeutic agent. 11. A pharmaceutical composition as claimed in claim 4 for oral administration. 12. A method of treatment of viral infections by administering a pharmaceutically safe and effective amount of a pharmaceutical composition according to claim 4.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.